{
  "Country": "PT",
  "PICOs": [
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with histologically documented KRAS G12C mutation who have progressed after at least one prior systemic therapy, including platinum-based dual chemotherapy and a checkpoint inhibitor, and no other known oncogenic mutation for which an approved target therapy exists.",
      "Intervention": "New medicine under assessment",
      "Comparator": "Docetaxel",
      "Outcomes": "Overall survival, progression-free survival, objective response rate, duration of response, disease control rate, time to progression, time to next treatment, adverse events."
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with histologically documented KRAS G12C mutation who have progressed after at least one prior systemic therapy.",
      "Intervention": "New medicine under assessment",
      "Comparator": "Docetaxel + Nintedanib",
      "Outcomes": "Overall survival, progression-free survival, objective response rate, duration of response, disease control rate, time to progression, time to next treatment, adverse events."
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with histologically documented KRAS G12C mutation who have progressed after at least one prior systemic therapy.",
      "Intervention": "New medicine under assessment",
      "Comparator": "Nivolumab",
      "Outcomes": "Overall survival, progression-free survival, objective response rate, duration of response, disease control rate, time to progression, time to next treatment, adverse events."
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with histologically documented KRAS G12C mutation who have progressed after at least one prior systemic therapy.",
      "Intervention": "New medicine under assessment",
      "Comparator": "Pembrolizumab",
      "Outcomes": "Overall survival, progression-free survival, objective response rate, duration of response, disease control rate, time to progression, time to next treatment, adverse events."
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with histologically documented KRAS G12C mutation who have progressed after at least one prior systemic therapy.",
      "Intervention": "New medicine under assessment",
      "Comparator": "Atezolizumab",
      "Outcomes": "Overall survival, progression-free survival, objective response rate, duration of response, disease control rate, time to progression, time to next treatment, adverse events."
    }
  ],
  "SourceType": "hta_submission"
}